AstraZeneca Studies Listing of New Vaccines Division_老虎社区_美港股上老虎

AstraZeneca Studies Listing of New Vaccines Division

Bloomberg2021-12-06

(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

大汉双林
·2021-12-06
Like
回复
1
举报
e13v3n
·2021-12-06
k
回复
1
举报
EHG
·2021-12-06
Like
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2188506527?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-06 08:20","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2188506527","market":"us","top_or_hot":-1,"title":"AstraZeneca Studies Listing of New Vaccines Division","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Studies Listing of New Vaccines Division</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Studies Listing of New Vaccines Division\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4017","symbol_name":"黄金","start_time":0,"source_url":"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html","article_id":"2188506527","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2188506527","pubTimestamp":1638750018,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4017":"黄金","AZN":"阿斯利康"},"translate_title":"阿斯利康研究新疫苗部门上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.\nThe U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.\nAstraZeneca said last month it’s creating a new vaccine and immune therapies division to house its Covid-19 inoculation and antibody treatment, as well as a flu shot and drug for respiratory syncytial virus. The division, to be led by executive Iskra Reic, will include teams from AstraZeneca’s research, manufacturing and commercial departments.\nChief Executive Officer Pascal Soriot is under pressure from shareholders as AstraZeneca’s stock lags behind rivals. The company has gained 6% over the past twelve months, while Pfizer Inc. has risen 35% and Moderna Inc. has jumped 90%.\nAstraZeneca said in November it would move to a profit model for the Covid-19 vaccine it created with the University of Oxford, having looked on as its competitors generated billions of dollars in sales from their immunizations.\nEarly in the pandemic, AstraZeneca pledged not to profit from its shot as long as the disease remained a pandemic. Soriot said it will now only seek to take a profit from wealthier nations, and will rely on tiered pricing to make sure its vaccine is affordable.\nAny move involving the vaccine business could be politically fraught, and AstraZeneca will need to be careful not to be seen as profiting too quickly as coronavirus infection rates rise and governments grapple to immunize populations. Deliberations are ongoing, and the company could ultimately decide against a listing if the idea triggers too much backlash, the people said.\nA representative for AstraZeneca couldn’t immediately comment.\nAstraZeneca has been taking other steps to beef up the new division. It effectively blocked Advent International’s $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker, Bloomberg News reported Friday. AstraZeneca objected to the deal as it was seeking to buy certain assets from the Nordic company that could potentially be housed within the vaccine unit, people with knowledge of the matter said.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":608224967,"gmtCreate":1638751234377,"gmtModify":1638751234482,"author":{"id":"3570058627460962","authorId":"3570058627460962","name":"大汉双林","avatar":"https://static.tigerbbs.com/543f4098b129bdebbefab1ff0cc5cf0a","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3570058627460962","authorIdStr":"3570058627460962"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608224967","repostId":2188506527,"repostType":4,"repost":{"id":"2188506527","kind":"news","pubTimestamp":1638750018,"share":"https://www.laohu8.com/m/news/2188506527?lang=&edition=full","pubTime":"2021-12-06 08:20","market":"us","language":"en","title":"AstraZeneca Studies Listing of New Vaccines Division","url":"https://stock-news.laohu8.com/highlight/detail?id=2188506527","media":"Bloomberg","summary":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-","content":"<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.</p>\n<p>The U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.</p>\n<p>AstraZeneca said last month it’s creating a new vaccine and immune therapies division to house its Covid-19 inoculation and antibody treatment, as well as a flu shot and drug for respiratory syncytial virus. The division, to be led by executive Iskra Reic, will include teams from AstraZeneca’s research, manufacturing and commercial departments.</p>\n<p>Chief Executive Officer Pascal Soriot is under pressure from shareholders as AstraZeneca’s stock lags behind rivals. The company has gained 6% over the past twelve months, while Pfizer Inc. has risen 35% and Moderna Inc. has jumped 90%.</p>\n<p>AstraZeneca said in November it would move to a profit model for the Covid-19 vaccine it created with the University of Oxford, having looked on as its competitors generated billions of dollars in sales from their immunizations.</p>\n<p>Early in the pandemic, AstraZeneca pledged not to profit from its shot as long as the disease remained a pandemic. Soriot said it will now only seek to take a profit from wealthier nations, and will rely on tiered pricing to make sure its vaccine is affordable.</p>\n<p>Any move involving the vaccine business could be politically fraught, and AstraZeneca will need to be careful not to be seen as profiting too quickly as coronavirus infection rates rise and governments grapple to immunize populations. Deliberations are ongoing, and the company could ultimately decide against a listing if the idea triggers too much backlash, the people said.</p>\n<p>A representative for AstraZeneca couldn’t immediately comment.</p>\n<p>AstraZeneca has been taking other steps to beef up the new division. It effectively blocked Advent International’s $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker, Bloomberg News reported Friday. AstraZeneca objected to the deal as it was seeking to buy certain assets from the Nordic company that could potentially be housed within the vaccine unit, people with knowledge of the matter said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Studies Listing of New Vaccines Division</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Studies Listing of New Vaccines Division\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2188506527","content_text":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.\nThe U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.\nAstraZeneca said last month it’s creating a new vaccine and immune therapies division to house its Covid-19 inoculation and antibody treatment, as well as a flu shot and drug for respiratory syncytial virus. The division, to be led by executive Iskra Reic, will include teams from AstraZeneca’s research, manufacturing and commercial departments.\nChief Executive Officer Pascal Soriot is under pressure from shareholders as AstraZeneca’s stock lags behind rivals. The company has gained 6% over the past twelve months, while Pfizer Inc. has risen 35% and Moderna Inc. has jumped 90%.\nAstraZeneca said in November it would move to a profit model for the Covid-19 vaccine it created with the University of Oxford, having looked on as its competitors generated billions of dollars in sales from their immunizations.\nEarly in the pandemic, AstraZeneca pledged not to profit from its shot as long as the disease remained a pandemic. Soriot said it will now only seek to take a profit from wealthier nations, and will rely on tiered pricing to make sure its vaccine is affordable.\nAny move involving the vaccine business could be politically fraught, and AstraZeneca will need to be careful not to be seen as profiting too quickly as coronavirus infection rates rise and governments grapple to immunize populations. Deliberations are ongoing, and the company could ultimately decide against a listing if the idea triggers too much backlash, the people said.\nA representative for AstraZeneca couldn’t immediately comment.\nAstraZeneca has been taking other steps to beef up the new division. It effectively blocked Advent International’s $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker, Bloomberg News reported Friday. AstraZeneca objected to the deal as it was seeking to buy certain assets from the Nordic company that could potentially be housed within the vaccine unit, people with knowledge of the matter said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":608267787,"gmtCreate":1638750387664,"gmtModify":1638750387878,"author":{"id":"3565819252889467","authorId":"3565819252889467","name":"e13v3n","avatar":"https://static.tigerbbs.com/387ab24895655e32d7ddaf87ded7da37","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3565819252889467","authorIdStr":"3565819252889467"},"htmlText":"k","listText":"k","text":"k","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608267787","repostId":2188506527,"repostType":4,"repost":{"id":"2188506527","kind":"news","pubTimestamp":1638750018,"share":"https://www.laohu8.com/m/news/2188506527?lang=&edition=full","pubTime":"2021-12-06 08:20","market":"us","language":"en","title":"AstraZeneca Studies Listing of New Vaccines Division","url":"https://stock-news.laohu8.com/highlight/detail?id=2188506527","media":"Bloomberg","summary":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-","content":"<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.</p>\n<p>The U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.</p>\n<p>AstraZeneca said last month it’s creating a new vaccine and immune therapies division to house its Covid-19 inoculation and antibody treatment, as well as a flu shot and drug for respiratory syncytial virus. The division, to be led by executive Iskra Reic, will include teams from AstraZeneca’s research, manufacturing and commercial departments.</p>\n<p>Chief Executive Officer Pascal Soriot is under pressure from shareholders as AstraZeneca’s stock lags behind rivals. The company has gained 6% over the past twelve months, while Pfizer Inc. has risen 35% and Moderna Inc. has jumped 90%.</p>\n<p>AstraZeneca said in November it would move to a profit model for the Covid-19 vaccine it created with the University of Oxford, having looked on as its competitors generated billions of dollars in sales from their immunizations.</p>\n<p>Early in the pandemic, AstraZeneca pledged not to profit from its shot as long as the disease remained a pandemic. Soriot said it will now only seek to take a profit from wealthier nations, and will rely on tiered pricing to make sure its vaccine is affordable.</p>\n<p>Any move involving the vaccine business could be politically fraught, and AstraZeneca will need to be careful not to be seen as profiting too quickly as coronavirus infection rates rise and governments grapple to immunize populations. Deliberations are ongoing, and the company could ultimately decide against a listing if the idea triggers too much backlash, the people said.</p>\n<p>A representative for AstraZeneca couldn’t immediately comment.</p>\n<p>AstraZeneca has been taking other steps to beef up the new division. It effectively blocked Advent International’s $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker, Bloomberg News reported Friday. AstraZeneca objected to the deal as it was seeking to buy certain assets from the Nordic company that could potentially be housed within the vaccine unit, people with knowledge of the matter said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Studies Listing of New Vaccines Division</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Studies Listing of New Vaccines Division\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2188506527","content_text":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.\nThe U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.\nAstraZeneca said last month it’s creating a new vaccine and immune therapies division to house its Covid-19 inoculation and antibody treatment, as well as a flu shot and drug for respiratory syncytial virus. The division, to be led by executive Iskra Reic, will include teams from AstraZeneca’s research, manufacturing and commercial departments.\nChief Executive Officer Pascal Soriot is under pressure from shareholders as AstraZeneca’s stock lags behind rivals. The company has gained 6% over the past twelve months, while Pfizer Inc. has risen 35% and Moderna Inc. has jumped 90%.\nAstraZeneca said in November it would move to a profit model for the Covid-19 vaccine it created with the University of Oxford, having looked on as its competitors generated billions of dollars in sales from their immunizations.\nEarly in the pandemic, AstraZeneca pledged not to profit from its shot as long as the disease remained a pandemic. Soriot said it will now only seek to take a profit from wealthier nations, and will rely on tiered pricing to make sure its vaccine is affordable.\nAny move involving the vaccine business could be politically fraught, and AstraZeneca will need to be careful not to be seen as profiting too quickly as coronavirus infection rates rise and governments grapple to immunize populations. Deliberations are ongoing, and the company could ultimately decide against a listing if the idea triggers too much backlash, the people said.\nA representative for AstraZeneca couldn’t immediately comment.\nAstraZeneca has been taking other steps to beef up the new division. It effectively blocked Advent International’s $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker, Bloomberg News reported Friday. AstraZeneca objected to the deal as it was seeking to buy certain assets from the Nordic company that could potentially be housed within the vaccine unit, people with knowledge of the matter said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":608264476,"gmtCreate":1638750323003,"gmtModify":1638750323279,"author":{"id":"3586941861951066","authorId":"3586941861951066","name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586941861951066","authorIdStr":"3586941861951066"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608264476","repostId":2188506527,"repostType":4,"repost":{"id":"2188506527","kind":"news","pubTimestamp":1638750018,"share":"https://www.laohu8.com/m/news/2188506527?lang=&edition=full","pubTime":"2021-12-06 08:20","market":"us","language":"en","title":"AstraZeneca Studies Listing of New Vaccines Division","url":"https://stock-news.laohu8.com/highlight/detail?id=2188506527","media":"Bloomberg","summary":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-","content":"<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.</p>\n<p>The U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.</p>\n<p>AstraZeneca said last month it’s creating a new vaccine and immune therapies division to house its Covid-19 inoculation and antibody treatment, as well as a flu shot and drug for respiratory syncytial virus. The division, to be led by executive Iskra Reic, will include teams from AstraZeneca’s research, manufacturing and commercial departments.</p>\n<p>Chief Executive Officer Pascal Soriot is under pressure from shareholders as AstraZeneca’s stock lags behind rivals. The company has gained 6% over the past twelve months, while Pfizer Inc. has risen 35% and Moderna Inc. has jumped 90%.</p>\n<p>AstraZeneca said in November it would move to a profit model for the Covid-19 vaccine it created with the University of Oxford, having looked on as its competitors generated billions of dollars in sales from their immunizations.</p>\n<p>Early in the pandemic, AstraZeneca pledged not to profit from its shot as long as the disease remained a pandemic. Soriot said it will now only seek to take a profit from wealthier nations, and will rely on tiered pricing to make sure its vaccine is affordable.</p>\n<p>Any move involving the vaccine business could be politically fraught, and AstraZeneca will need to be careful not to be seen as profiting too quickly as coronavirus infection rates rise and governments grapple to immunize populations. Deliberations are ongoing, and the company could ultimately decide against a listing if the idea triggers too much backlash, the people said.</p>\n<p>A representative for AstraZeneca couldn’t immediately comment.</p>\n<p>AstraZeneca has been taking other steps to beef up the new division. It effectively blocked Advent International’s $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker, Bloomberg News reported Friday. AstraZeneca objected to the deal as it was seeking to buy certain assets from the Nordic company that could potentially be housed within the vaccine unit, people with knowledge of the matter said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Studies Listing of New Vaccines Division</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Studies Listing of New Vaccines Division\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","BK4017":"黄金"},"source_url":"https://finance.yahoo.com/news/astrazeneca-studies-listing-vaccines-division-174218900.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2188506527","content_text":"(Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said.\nThe U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.\nAstraZeneca said last month it’s creating a new vaccine and immune therapies division to house its Covid-19 inoculation and antibody treatment, as well as a flu shot and drug for respiratory syncytial virus. The division, to be led by executive Iskra Reic, will include teams from AstraZeneca’s research, manufacturing and commercial departments.\nChief Executive Officer Pascal Soriot is under pressure from shareholders as AstraZeneca’s stock lags behind rivals. The company has gained 6% over the past twelve months, while Pfizer Inc. has risen 35% and Moderna Inc. has jumped 90%.\nAstraZeneca said in November it would move to a profit model for the Covid-19 vaccine it created with the University of Oxford, having looked on as its competitors generated billions of dollars in sales from their immunizations.\nEarly in the pandemic, AstraZeneca pledged not to profit from its shot as long as the disease remained a pandemic. Soriot said it will now only seek to take a profit from wealthier nations, and will rely on tiered pricing to make sure its vaccine is affordable.\nAny move involving the vaccine business could be politically fraught, and AstraZeneca will need to be careful not to be seen as profiting too quickly as coronavirus infection rates rise and governments grapple to immunize populations. Deliberations are ongoing, and the company could ultimately decide against a listing if the idea triggers too much backlash, the people said.\nA representative for AstraZeneca couldn’t immediately comment.\nAstraZeneca has been taking other steps to beef up the new division. It effectively blocked Advent International’s $7.6 billion takeover of Swedish Orphan Biovitrum AB by withholding its 8% stake in the drugmaker, Bloomberg News reported Friday. AstraZeneca objected to the deal as it was seeking to buy certain assets from the Nordic company that could potentially be housed within the vaccine unit, people with knowledge of the matter said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":61,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}